INDICATORS NT-PROBNP and ST-2 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION
https://doi.org/10.15372/ATER20170403
Abstract
The goal was to study clinical features, NTproBNP and ST-2 indices in patients with acute myocardial infarction with ST segment elevation (STEMI) complicated by heart failure. Materials and methods. Included 150 patients with STEMI in the first 24 hours from the onset of the disease, with arterial hypertension, acute heart failure (AHF), Killip I-IV degree. All patients underwent clinical, laboratory and instrumental examinations: on admission to the hospital (first visit) and discharge (second visit). Results. The average age of the patients was 61.70 ± 2.96 years. In the dynamics of treatment of STEMI patients in the general group, a decrease in the level of ST-2 was observed against a background of high concentration of NTproBNP. With the progression of the degree of AHF Killip II-IV, the level of ST-2 and NTproBNP increases. At the first visit in the ST-2 ≥ 35 ng/mL group, the ST-2 and NTproBNP levels were statistically higher than those in the ST-2 group <35 ng/ml. At the second visit in ST-2 ≥ 35 ng/ml group, ST-2 level was decreased, and NTproBNP values remained high in the studied groups. A statistically significant reduction in the ejection fraction in patients with ST-2 ≥ 35 ng/ml was found to be statistically significant compared to the ST-2 group <35 ng/ml. The conclusion. In STEMI patients, ST-2 and NTproBNP are prognostic markers for the progression of acute heart failure. In the dynamics of inpatient treatment, the level of ST-2 persisted more than 35 ng/ml, in the ST-2 group of 35 ng/ml has the most unfavorable prognosis of heart failure.
About the Authors
E. V. Khorolets
Rostov State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
L. A. Khaisheva
Rostov State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
S. V. Shlyk
Rostov State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
References
1. Шальнова С.A., Конради А.О., Карпов Ю.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России» // Рос. кардиол. журн. 2012. Т. 5. С. 6-10.
2. DeBold A., Borenstein H., Veress A. et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial exrtract in rats // Life Sci. 1981. Vol. 28. P. 89-94.
3. Purification and complete amino acid sequence of a-human atrial natriuretic peptide (a-hANP) // Biochem. Biophys. Res. Commun. 1984. Vol. 118. P. 131-139.
4. Globits S., Frank H., Pacher B. et al. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure // Am. Heart J. 1998. Vol. 135. P. 592-597.
5. Maeda K., Tsutamoto T., Wada A. et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end diastolic pressure in patients with symptomatic left ventricular dysfunction // Am. Heart J. 1998. Vol. 135. P. 825-832.
6. Kazanegra R., van Cheng, Garcia A. et al. A rapid test for B-type natriuretic peptide correlates with filling wedge pressure in patients treated for decompensated heart failure: a pilot study // J. Car. Fail. 2001. Vol. 7. P. 21-29.
7. Phillips R., Ardelijan M., Shimabukuro S. et al. Normalisation of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension // JACC. 1991. Vol. 17. P. 1595-1602.
8. Khan S.Q., Dhillon O., Kelly D. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional proatrial natriuretic peptide: The LAMP (Leicester Acute Myocardial Infarction Peptide) Study // J. Amer. Coll. Cardiol. 2008. Vol. 51. P. 1857-1864.
9. Khan S.Q., Quinn P., Davies J.E. et al. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction // Heart. 2008. Vol. 94. P. 40-43.
10. Omland T., de Lemos J.A. Amino-terminal Pro-B-type natriuretic peptides in stable and unstable ischemic heart disease // Amer. J. Cardiol. 2008. Vol. 101 (Suppl. 3A). P. 61-66.
11. Kim Y., Yang D., Park Y. et al. Incremental Prognostic Value of C-Reactive Protein and N-Terminal ProB-Type Natriuretic Peptide in Acute Coronary Syndrome // Circulation J. 2006. Vol. 70. Р. 1379-1384.
12. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., Mc-Clanahan T.K. et al. IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines // Immunity. 2005. Vol. 23 (5). P. 479-490.
13. Daniels L.B., Clopton P., Iqbal N. et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients // Am. Heart J. 2010. Vol. 160. P. 721-728.
14. Ciccone M.M., Cortese F., Gesualdo M. et al. A Novel Cardiac Bio-Marker: ST2: A Review // Molecules. 2013. Vol. 18, N 15. P. 314-328.
15. Diez J. Serum soluble ST2 as a biochemical marker of acute heart failure // J. Am. Coll. Cardiol. 2008. Vol. 52. P. 1466-1467.
16. Kakkar R., Lee R.T. The IL-33/ST2 pathway: Therapeutic target and novel biomarker // Nat. Rev. Drug. Discov. 2008. Vol. 7 (10). P. 827-840.
17. Bartunek J., Delrue L., van Durme F. et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load // J. Am. Coll. Cardiol. 2008. Vol. 52 (25). P. 2166-2174.
18. Bhardwaj A., Januzzi J.L.Jr. ST2: a novel biomarker for heart failure // Expert Rev. Mol. Diagn. 2010. Vol. 10. P. 459-464.
19. Lupуn J., Antonio M., Galán A. et al. Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratifi cation vs Conventional Assessment // Mayo Clin. Proc. 2013. Vol. 88 (3). P. 234-243.
20. Baba Y., Maeda K., Yashiro T. et al. GATA2 is a critical transactivator for thehuman IL1RL1/ST2 promoter in mast cells/basophils: Opposing roles for GATA2 and GATA1 in human IL- 1RL1/ST2 gene expression // J. Biol. Chem. 2012. Vol. 287 (39). P. 32 689-32 696.
21. Ho J.E., Chen W.Y., Chen M.H. et al. Common genetic variation at the IL1RL1locus regulates IL-33/ST2 signaling // J. Clin. Invest. 2013. Vol. 123 (10). P. 4208-4218.
22. Boisot S., Beede J., Isakson S. et al. Serial sampling of ST2 predicts 90-day mortality following destabilized HF // J. Card. Fail. 2008. Vol. 14 (9). P. 732-738.
23. James L. Januzzi, Domingo Pascual-Figal, Lori B. Daniels. MPHc International coordinated commission on ST2 // Am. J. Cardiol. 2015. Suppl: 1A-6A. http://www.ajconline.org/issue/S0002-9149(15)X0003-8).
24. Seki K., Sanada S., Kudinova A.Y. et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling // Circ. Heart Fail. 2009. Vol. 2. P. 684-691.
25. Daniels L.B., Clopton P., Iqbal N. et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients // Am. Heart J. 2010. Vol. 160. P. 721-728.
26. Shah R., Chen-Tournoux A., Picard M. et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea // Circ. Heart Fail. 2009. Vol. 2. P. 311-319.
Review
For citations:
Khorolets E.V., Khaisheva L.A., Shlyk S.V. INDICATORS NT-PROBNP and ST-2 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION. Ateroscleroz. 2017;13(4):17-24. (In Russ.) https://doi.org/10.15372/ATER20170403
Views:
208
Email this article 